Contact us
Close this search box.

European Innovation Council Awards €2.5 Million Grant to Trince, NecstGen, and IBSAL for Advancing Cell Therapy Manufacturing

“We are grateful for the EIC’s support in funding the Penphomet project. It demonstrates that our breakthrough technology is addressing a crucial gap in the field of cell therapy,” said Philip Mathuis, CEO at Trince. “Together with our partners NecstGen and IBSAL, we are committed to advancing cell therapy manufacturing, ultimately benefiting patients and healthcare systems.”

Read more about the Penphomet Project with NecstGen, IBSAL and Trince.

Read More